Clinical Trials · NCT04487444
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Rhode Island Hospital
- Enrollment
- 56
- Start date
- Sep 2020
- Locations
- 1 site, United States
- Primary endpoint
- Time to recovery (free of respiratory failure)